{"id":"W1988787726","doi":"10.1016/j.critrevonc.2014.10.007","title":"Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?","year":2014,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Pleiotrophin; Midkine; Angiogenesis; Angiogenin; Cancer research; Basic fibroblast growth factor; Haematopoiesis; Growth factor; Immunology; Vascular endothelial growth factor; Chronic lymphocytic leukemia; Placental growth factor; Medicine; Angiopoietin; Biology; Internal medicine; Leukemia; Stem cell; Cell biology; Receptor; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.003822766,0.001723101,0.01608956,0.001603986,0.0001117004,0.00005413894,0.001463202,0.004129681,0.001826767],"category_scores_gemma":[0.01296689,0.001311328,0.002187272,0.002097228,0.001836569,0.000143459,0.0008285685,0.003497786,0.002852577],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.2153807,"about_ca_system_score_gemma":0.09389165,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001868208,"about_ca_topic_score_gemma":0.0006694287,"domain_scores_codex":[0.9845784,0.003973208,0.005237296,0.002396133,0.0007949013,0.003020013],"domain_scores_gemma":[0.9851252,0.01047154,0.0007039192,0.002470189,0.0002173837,0.001011813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001022586,0.0003446209,0.00005404417,0.2427135,0.0002104352,0.005340952,0.0001158432,9.944156e-7,0.000001263643,0.02591305,0.01036141,0.7148416],"study_design_scores_gemma":[0.00681605,0.0008395031,0.000001381179,0.1470619,0.001050956,0.006570317,0.00004295665,0.0001895562,0.000003590828,0.0006962998,0.8358968,0.0008306865],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006047775,0.9893747,0.00009330536,0.0004409305,0.000942899,0.005167769,0.00003278465,0.0001094264,0.003777684],"genre_scores_gemma":[0.0003686839,0.9958773,0.0004030429,0.0001658732,0.0005290341,0.001789781,0.00008116052,0.0002711565,0.0005140216],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8255354,"threshold_uncertainty_score":0.9995515,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1025489608667844,"score_gpt":0.4668439690545231,"score_spread":0.3642950081877387,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}